Effects of local vibration therapy and gabapentin on restless legs syndrome symptoms: a randomized controlled trial.
4 affiliations
- 1Neuromusculoskeletal Research Center, Department of Physical Medicine and Rehabilitation, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- 2Neuromusculoskeletal Research Center, Department of Physical Medicine and Rehabilitation, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. [email protected].
- 3Neuromusculoskeletal Research Center, Department of Physical Medicine and Rehabilitation, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. [email protected].
- 4Clinical Biomechanics and Ergonomics Research Center, Department of Physical Medicine and Rehabilitation, AJA University of Medical Sciences, Tehran, Iran.
Abstract
Objective
This study aimed to evaluate the effect of LV in combination with gabapentin, a first-line medication for RLS, on the treatment of patients with the condition.Results
In total, 36 participants (18 in each group) participated in this study, with 10 (55%) being male within each group. The mean age of participants was 45 years (SD = 10.6) in the LV group and 49.1 (SD = 8.3) in the gabapentin group. In both the LV and gabapentin groups, IRLSSG scores decreased significantly after the intervention compared with baseline (p < 0.001). However, scores increased at the one-month follow-up, although they remained lower than pre-intervention values (p < 0.001). A similar pattern was observed for the PSQI scores (p < 0.001). There were no significant differences between groups at any timepoint (p > 0.05).Trial registration
The study protocol was registered at the Iranian Registry of Clinical Trials on August 30th, 2023 (code IRCT20190306042945N4).
Related
- Percussive Vibration Therapy as an Adjunct to Conventional Physiotherapy in Chronic Non-Specific Low Back Pain: A Randomized Controlled Trial
- Eight-week flexi-bar vibration exercise improves cardiovascular function accompanied by altered gut microbiota and metabolites in middle-aged and elderly women: a randomized controlled trial
- Effects of Sleeve Gastrectomy and Subsequent Whole-Body Vibration Training on Resting Metabolic Rate and Body Composition: A Pilot Randomized Controlled Trial
- Irritable bowel syndrome and restless legs syndrome: a narrative review of epidemiological and pathophysiological overlap
- Prevalence and associated factors of poor sleep quality, restless legs syndrome, insomnia, and sleep apnea in hemodialysis patients: a systematic review and meta-analysis
BibTeX
@article{raissi2026effects,
title = {{Effects of local vibration therapy and gabapentin on restless legs syndrome symptoms: a randomized controlled trial.}},
author = {Gholamreza Raissi and Bijan Forogh and Hamid Ansari and Seyed Pezhman Madani and Masumeh Bagherzadeh Cham and Hosna Soleymanzadeh},
journal = {BMC research notes},
year = {2026},
month = jul,
doi = {10.1186/s13104-026-07918-z},
url = {https://europepmc.org/article/MED/42908006},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Effects of local vibration therapy and gabapentin on restless legs syndrome symptoms: a randomized controlled trial.
AU - Gholamreza Raissi
AU - Bijan Forogh
AU - Hamid Ansari
AU - Seyed Pezhman Madani
AU - Masumeh Bagherzadeh Cham
AU - Hosna Soleymanzadeh
PY - 2026
DA - 2026/07/01
JO - BMC research notes
DO - 10.1186/s13104-026-07918-z
UR - https://europepmc.org/article/MED/42908006
AB - Objective This study aimed to evaluate the effect of LV in combination with gabapentin, a first-line medication for RLS, on the treatment of patients with the condition.Results In total, 36 participants (18 in each group) participated in this study, with 10 (55%) being male within each group. The mean age of participants was 45 years (SD = 10.6) in the LV group and 49.1 (SD = 8.3) in the gabapentin group. In both the LV and gabapentin groups, IRLSSG scores decreased significantly after the intervention compared with baseline (p < 0.001). However, scores increased at the one-month follow-up, although they remained lower than pre-intervention values (p < 0.001). A similar pattern was observed for the PSQI scores (p < 0.001). There were no significant differences between groups at any timepoint (p > 0.05).Trial registration The study protocol was registered at the Iranian Registry of Clinical Trials on August 30th, 2023 (code IRCT20190306042945N4).
SN - 1756-0500
ER -